AHA Video: SMART AV does not reveal clear path to assisting CRT non-responders
Approximately 30 percent of patients who receive a CRT device experience a limited benefit to the therapy. Ellenbogen reviews the goals and objectives of seeking an improved outcome in these patients, along with different outcomes in different patient subgroups and the economic considerations for clinical practice based on these findings.
CORRECTION: In the video interview, the interviewer refers to the trial as the SMART AF trial, when in fact, the trial is titled SMART AV. Our apologies for the error.